Atlas Trials

Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

Clinical trial NCT00240994 · COMPLETED

Trial details

NCT number
NCT00240994
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Kidney Failure, ChronicKidney TransplantationImmunosuppression
Start date
2005-01-01
Primary completion
2009-11-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.